MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma

被引：0
作者：
Ting Li [1 ]
Ruwei Xing [2 ]
Lijie Xiang [1 ]
Haotian Liu [2 ]
Junqiang Wei [1 ]
Jia Lu [2 ]
Tao Li [1 ]
Jilong Yang [2 ]
机构：
[1] Tianjin Medical University Cancer Institute and Hospital,Departments of Bone and Soft Tissue Tumor
[2] Tianjin’s Clinical Research Center for Cancer,National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
[3] The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Department of Bone and Soft
[4] Chinese Academy of Sciences,Tissue Surgery, Institute of Basic Medicine and Cancer (IBMC)
来源：
Holistic Integrative Oncology | / 3卷 / 1期
关键词：
Melanoma; PD-L1; MIIP; HDAC6; Immunotherapy;
D O I：
10.1007/s44178-024-00094-9
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 348 条
[1]  
Hao MZ(2014)Novel anti-melanoma treatment: focus on immunotherapy Chin J Cancer 33 458-465
[2]  
Zhou WY(2015)Advances in targeted therapy for unresectable melanoma: new drugs and combinations Cancer Lett 359 1-8
[3]  
Du XL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30
[4]  
Chen KX(2016)Essential role of HDAC6 in the regulation of PD-L1 in melanoma Mol Oncol. 10 735-750
[5]  
Wang GW(2019)Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Ann Oncol 30 582-588
[6]  
Yang Y(2017)The immunology of melanoma Clin Lab Med 37 449-471
[7]  
Yang JL(2017)Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade Cell 170 1120-1133.e1117
[8]  
Hao M(2016)Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody Pembrolizumab in melanoma J Clin Oncol 34 4102-4109
[9]  
Song F(2012)Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2455-2465
[10]  
Du X(2013)Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma N Engl J Med 369 134-144
12345678910